Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL

May 21st 2025

Tafasitamab plus lenalidomide has received NMPA approval for patients with relapsed/refractory DLBCL who are ineligible for ASCT.

Dr Falchi on the Safety of Fixed-Duration Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

May 20th 2025

Lorenzo Falchi, MD, discusses the safety and pharmacodynamics of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma

Lymphodepletion Enhances MAR T-Cell Expansion and Persistence in R/R Lymphoma

May 20th 2025

Lymphodepletion was associated with enhanced MAR T-cell response and antitumor activity with MT-601 in patients with relapsed/refractory lymphoma.

FDA ODAC Votes Against the Applicability of STARGLO Data for Glofitamab Plus Chemo for U.S. Patients With R/R DLBCL

May 20th 2025

The FDA’s ODAC voted against the applicability of STARGLO trial results to U.S. patients with relapsed/refractory DLBCL.

Hematology Experts Outline the Top Abstracts to Watch at the 2025 ASCO Annual Meeting

May 19th 2025

Oncology experts detail their most highly-anticipated hematology abstracts and data to watch at the upcoming 2025 ASCO Annual Meeting.

Dr Oluwole on the Importance of Assessing the Onset and Incidence of Axi-Cel–Related Neurotoxicity in R/R DLBCL

May 16th 2025

Olalekan O. Oluwole, MD, MPH, discusses how AE assessment could guide post-infusion monitoring periods and outpatient axi-cel administration in LBCL.

Dr Patel on the Safety Profile of Bispecific Antibodies in Follicular Lymphoma

May 14th 2025

Vivek G. Patel, MD, discusses the safety profile of bispecific antibodies for the treatment of patients with follicular lymphoma.

Dr Falchi on the Efficacy of Fixed-Duration Epcoritamab Plus Lenalidomide and Rituximab in R/R Follicular Lymphoma

May 14th 2025

Lorenzo Falchi, MD, discusses the safety and efficacy of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

AlloNK Plus Rituximab Induces Durable Responses in R/R B-Cell NHL

May 14th 2025

Longer-term phase 1/2 data with AB-101 plus rituximab showed high, durable responses in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Generic Eltrombopag Is Now Available for Severe Aplastic Anemia and Immune Thrombocytopenia

May 14th 2025

Generic formulations of eltrombopag are now available for severe aplastic anemia and immune thrombocytopenia.

Inflation Reduction Act Leads to Seesaw Effect Between Oncologic Drug Savings and Development

May 9th 2025

Challenges may arise as there could be unintended consequences on oncologic drug development, access, and innovation.

FDA Lifts Clinical Hold on Tabelecleucel Trial for EBV+ Post-Transplant Lymphoproliferative Disease

May 8th 2025

FDA lifts clinical hold on tabelecleucel IND, enabling trial resumption in EBV+ PTLD following HSCT or SOT in relapsed/refractory patients.

The OncFive: Top Oncology Articles for the Week of 4/27

May 3rd 2025

The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission, and more.

FDA Grants Fast Track Designation to BI-1808 in Select Cutaneous T-Cell Lymphoma

May 3rd 2025

BI-1808 has received FDA fast track designation for the treatment of patients with select cutaneous T-cell lymphoma subtypes.

Dr Patel on Choosing Between Mosunetuzumab and Epcoritamab in Follicular Lymphoma

May 2nd 2025

Vivek G Patel, MD, discusses the comparative efficacy and safety profiles of mosunetuzumab and epcoritamab in follicular lymphoma.

sBLA Submission Planned for Epcoritamab/Rituximab/Lenalidomide in R/R FL

May 2nd 2025

An sBLA seeking the approval of epcoritamab plus rituximab and lenalidomide for relapsed/refractory FL is planned to be submitted to the FDA.

ICT01 Plus Azacitidine and Venetoclax Shows Early Evidence of Antitumor Activity in AML

April 29th 2025

A low dose of ICT01 added to combination therapy with azacitidine and venetoclax proved active and safe as frontline therapy in patients with AML.

Addition of Relatlimab/Nivolumab to Azacitidine/Venetoclax Shows Safety, Early Efficacy in Adverse-Risk Frontline AML

April 29th 2025

Although the combination of azacitidine alone plus relatlimab/nivolumab was deemed safe, it had limited efficacy in patients with relapsed/refractory AML.

Five Under 5: Top Oncology Videos for the Week of 4/20

April 27th 2025

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

CHMP Recommends Brentuximab Vedotin Plus ECADD for Newly Diagnosed Stage IIB/III/IV Hodgkin Lymphoma

April 25th 2025

The EMA’s CHMP has recommended the approval of brentuximab vedotin plus ECADD for newly diagnosed, stage IIB/III/IV Hodgkin lymphoma.